Errors in Figure 2 and Table 3

In the Original Investigation titled “Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial,” which was published online April 13, 2022, and in print in the May 2022 issue,¹ there were errors in the key for Figure 2 A and B and in footnote f in Table 3. The key for Figure 2 A and B should be “Ixekizumab” (closed circles) and “Placebo” (open circles). In Table 3, footnote f should state that all cases of inflammatory bowel disease were Crohn disease. This article was corrected online.